Limits...
Prognostic value of CD166 expression in cancers of the digestive system: a systematic review and meta-analysis.

Ni C, Zhang Z, Zhu X, Liu Y, Qu D, Wu P, Huang J, Xu AX - PLoS ONE (2013)

Bottom Line: In colorectal cancer specifically, the results of a fixed-effects model indicated that CD166-positive expression was an independent marker associated with a smaller tumor burden (T category; RR = 0.93, 95%, CI: 0.88-0.98) but worse spread to nearby lymph nodes (N category; RR = 1.17, 95% CI: 1.05-1.30).The 5-year overall survival rate was showed relationship with cytoplasmic positive staining of CD166 (RR = 1.47 95% 1.21-1.79), but no significant association was found in the pool or any other stratified analysis with 3- or 5- year overall survival rate.Besides, our results also find CD166 expression indicate advanced T category and N-positive status in colorectal cancer specifically.

View Article: PubMed Central - PubMed

Affiliation: Cancer Institute, Key Laboratory of Cancer Prevention and Intervention, National Ministry of Education, Provincial Key Laboratory of Molecular Biology in Medical Sciences, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.

ABSTRACT

Objective: Many studies have reported the prognostic predictive value of CD166 as a cancer stem cell marker in cancers of the digestive system; however, its predictive value remains controversial. Here, we investigate the correlation between CD166 positivity in digestive system cancers and clinicopathological features using meta-analysis.

Methods: A comprehensive search in PubMed and ISI Web of Science through March of 2013 was performed. Only articles containing CD166 antigen immunohistochemical staining in cancers of the digestive system were included,including pancreatic cancer, esophageal cancer, gastric cancer and colorectal cancer. Data comparing 3- and 5-year overall survival along with other clinicopathological features were collected.

Results: Nine studies with 2553 patients who met the inclusion criteria were included for the analysis. The median rate of CD166 immunohistochemical staining expression was 56% (25.4%-76.3%). In colorectal cancer specifically, the results of a fixed-effects model indicated that CD166-positive expression was an independent marker associated with a smaller tumor burden (T category; RR = 0.93, 95%, CI: 0.88-0.98) but worse spread to nearby lymph nodes (N category; RR = 1.17, 95% CI: 1.05-1.30). The 5-year overall survival rate was showed relationship with cytoplasmic positive staining of CD166 (RR = 1.47 95% 1.21-1.79), but no significant association was found in the pool or any other stratified analysis with 3- or 5- year overall survival rate.

Conclusion: Based on the published studies, different cellular location of CD166 has distinct prognostic value and cytoplasmic positive expression is associated with worse prognosis outcome. Besides, our results also find CD166 expression indicate advanced T category and N-positive status in colorectal cancer specifically.

Show MeSH

Related in: MedlinePlus

CD166 stratified on staining pattern and 5-year overall survival rate in digestive cancer patients.
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC3733726&req=5

pone-0070958-g002: CD166 stratified on staining pattern and 5-year overall survival rate in digestive cancer patients.

Mentions: The 5-year overall survival rate was extracted from 9 studies, which was composed of 4 colorectal cancer studies, 1 gastric, 1 esophageal and 3 pancreatic cancer study and two studies of pancreatic cancer were also examined with 3-year overall survival. The pooled 5-year overall survival rates of CD166-positive and CD166-negative patients were 57.3% (767/1339) and 33.7% (523/1214), respectively. The 3-year overall survival rates were 25.3% (38/150) and 12.2% (17/139) for the same patients, respectively. The pool analysis did not show significant association between overall survival rate and CD166 status (Figures S5 and S6), however, the stratified group based on staining pattern revealed membrane and cytoplasmic staining was related with worse prognosis (RR = 1.47 95%CI 1.21–1.79), but the membrane staining alone could not show any prediction value (Table 2, Figure 2).


Prognostic value of CD166 expression in cancers of the digestive system: a systematic review and meta-analysis.

Ni C, Zhang Z, Zhu X, Liu Y, Qu D, Wu P, Huang J, Xu AX - PLoS ONE (2013)

CD166 stratified on staining pattern and 5-year overall survival rate in digestive cancer patients.
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC3733726&req=5

pone-0070958-g002: CD166 stratified on staining pattern and 5-year overall survival rate in digestive cancer patients.
Mentions: The 5-year overall survival rate was extracted from 9 studies, which was composed of 4 colorectal cancer studies, 1 gastric, 1 esophageal and 3 pancreatic cancer study and two studies of pancreatic cancer were also examined with 3-year overall survival. The pooled 5-year overall survival rates of CD166-positive and CD166-negative patients were 57.3% (767/1339) and 33.7% (523/1214), respectively. The 3-year overall survival rates were 25.3% (38/150) and 12.2% (17/139) for the same patients, respectively. The pool analysis did not show significant association between overall survival rate and CD166 status (Figures S5 and S6), however, the stratified group based on staining pattern revealed membrane and cytoplasmic staining was related with worse prognosis (RR = 1.47 95%CI 1.21–1.79), but the membrane staining alone could not show any prediction value (Table 2, Figure 2).

Bottom Line: In colorectal cancer specifically, the results of a fixed-effects model indicated that CD166-positive expression was an independent marker associated with a smaller tumor burden (T category; RR = 0.93, 95%, CI: 0.88-0.98) but worse spread to nearby lymph nodes (N category; RR = 1.17, 95% CI: 1.05-1.30).The 5-year overall survival rate was showed relationship with cytoplasmic positive staining of CD166 (RR = 1.47 95% 1.21-1.79), but no significant association was found in the pool or any other stratified analysis with 3- or 5- year overall survival rate.Besides, our results also find CD166 expression indicate advanced T category and N-positive status in colorectal cancer specifically.

View Article: PubMed Central - PubMed

Affiliation: Cancer Institute, Key Laboratory of Cancer Prevention and Intervention, National Ministry of Education, Provincial Key Laboratory of Molecular Biology in Medical Sciences, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.

ABSTRACT

Objective: Many studies have reported the prognostic predictive value of CD166 as a cancer stem cell marker in cancers of the digestive system; however, its predictive value remains controversial. Here, we investigate the correlation between CD166 positivity in digestive system cancers and clinicopathological features using meta-analysis.

Methods: A comprehensive search in PubMed and ISI Web of Science through March of 2013 was performed. Only articles containing CD166 antigen immunohistochemical staining in cancers of the digestive system were included,including pancreatic cancer, esophageal cancer, gastric cancer and colorectal cancer. Data comparing 3- and 5-year overall survival along with other clinicopathological features were collected.

Results: Nine studies with 2553 patients who met the inclusion criteria were included for the analysis. The median rate of CD166 immunohistochemical staining expression was 56% (25.4%-76.3%). In colorectal cancer specifically, the results of a fixed-effects model indicated that CD166-positive expression was an independent marker associated with a smaller tumor burden (T category; RR = 0.93, 95%, CI: 0.88-0.98) but worse spread to nearby lymph nodes (N category; RR = 1.17, 95% CI: 1.05-1.30). The 5-year overall survival rate was showed relationship with cytoplasmic positive staining of CD166 (RR = 1.47 95% 1.21-1.79), but no significant association was found in the pool or any other stratified analysis with 3- or 5- year overall survival rate.

Conclusion: Based on the published studies, different cellular location of CD166 has distinct prognostic value and cytoplasmic positive expression is associated with worse prognosis outcome. Besides, our results also find CD166 expression indicate advanced T category and N-positive status in colorectal cancer specifically.

Show MeSH
Related in: MedlinePlus